Publication Date:
2020-11-05
Description:
Background: Mutations in isocitrate dehydrogenase 1/2 (mIDH) are collectively found in up to 20% of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Reversible inhibitors of IDH1 (ivosidenib) and IDH2 (enasidenib) are currently approved and achieve response rates of ~40%, with median duration of response of
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink